Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

In Alzheimer's disease (AD), soluble oligomers of amyloid-β (Aβ) are emerging as a crucial
entity in driving disease progression as compared to insoluble amyloid deposits. The lacuna …

An increasing number of human diseases has been shown to be linked to aggregation and
amyloid formation by intrinsically disordered proteins (IDPs). Amylin, amyloid-β, and α …

Alzheimer's disease (AD) is an irreversible neurodegenerative disease, causing profound
social and economic implications. Early diagnosis and treatment of AD have faced great …

Alzheimer's disease (AD) pathology is characterized by loss of memory cognitive and
behavioral deterioration. One of the hallmarks of AD is amyloid β (Aβ) plaques in the brain …

In humans, β-amyloid and islet amyloid polypeptide (IAPP, also known as amylin)
aggregations are linked to Alzheimer's disease and type-2 diabetes, respectively. There is …

Lipid binding kinetics and energetics of self-aggregated and disordered beta-amyloid
oligomers of various sizes, from solution to lipid raft surfaces, were investigated using MD …

Aggregation of amyloid-β (Aβ) peptides is characteristic of Alzheimer's disease (AD), which
is the most common neurodegenerative disorder. Increasing evidence shows that Aβ …

Alzheimer's disease (AD) is a major cause of dementia characterized by the overexpression
of transmembrane amyloid precursor protein and its neurotoxic byproduct amyloid beta (Aβ) …

By virtue of their small size, nanomaterials can cross the blood-brain barrier and, when
modified to target specific cells or regions, can achieve high bioavailability at the intended …